MapLight (MPLT) officer Jonathan Gillis granted RSUs and 24,455 options

Rhea-AI Filing Summary

MapLight Therapeutics executive Jonathan Gillis received new equity awards in the form of stock options and restricted stock units (RSUs). On February 5, 2026, he was granted 24,455 employee stock options to buy voting common stock and 6,020 RSUs of voting common stock.

The RSUs vest over time, with one-quarter vesting on January 1, 2027 and the remainder vesting in equal installments each April 1, July 1, October 1, and January 1 thereafter, subject to continued service. The options vest with one-quarter on February 5, 2027 and the rest in equal monthly installments, also contingent on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider GILLIS JONATHAN

Role CAAO and PAO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	24,455	$0.00	--
Grant/Award	Voting Common Stock	6,020	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 24,455 shares (Direct); Voting Common Stock — 254,523 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GILLIS JONATHAN

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CAAO and PAO

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	02/05/2026		A		6,020(1)	A	$0(2)	254,523	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$15.7	02/05/2026		A		24,455		(3)	02/04/2036	Voting Common Stock	24,455	$0	24,455	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date.

2. Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

3. 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider equity awards did MapLight (MPLT) grant to Jonathan Gillis?

MapLight granted Jonathan Gillis 24,455 employee stock options and 6,020 restricted stock units (RSUs) of voting common stock. These awards are part of his equity compensation and vest over several years, contingent on his continued service with the company.

When do Jonathan Gillis’s RSUs at MapLight (MPLT) vest?

The RSUs vest over time. One-quarter vests on January 1, 2027, with 1/16 of the RSUs then vesting on each April 1, July 1, October 1, and January 1 thereafter, as long as he continues to serve the company on each vesting date.

How do the new stock options for Jonathan Gillis at MapLight (MPLT) vest?

The 24,455 employee stock options vest gradually. One-quarter vests on February 5, 2027, and the remaining shares vest in 1/48 monthly installments on the same calendar day each month, subject to his continued service through each vesting date.

What does each RSU granted to Jonathan Gillis by MapLight (MPLT) represent?

Each RSU represents a contingent right to receive one share of voting common stock of MapLight Therapeutics. The RSUs convert into actual shares only as they vest, and vesting depends on Jonathan Gillis continuing to serve the company on the scheduled dates.

How many MapLight (MPLT) shares does Jonathan Gillis own after these transactions?

After the 6,020-share RSU award, Jonathan Gillis beneficially owns 254,523 shares of voting common stock directly. In addition, he holds 24,455 employee stock options that give him the right to purchase additional shares as they vest and become exercisable.

What role does Jonathan Gillis hold at MapLight (MPLT) in this Form 4 filing?

In this filing, Jonathan Gillis is reported as an officer of MapLight Therapeutics with the title CAAO and PAO. The equity awards disclosed, including RSUs and stock options, are part of his compensation in that executive capacity with the company.